Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats.
暂无分享,去创建一个
R. Bellantone | M. Muscaritoli | P. Costelli | F. Rossi Fanelli | M. Bossola | G. Bonelli | F. Baccino | G. Doglietto | F. Fanelli | G. Grieco | R. Bellantone | Maurizio Bossola | M. Muscaritoli | GB Doglietto
[1] R. Bellantone,et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[2] P. Costelli,et al. Activation of Ca2+-dependent proteolysis in skeletal muscle and heart in cancer cachexia , 2001, British Journal of Cancer.
[3] M. Tisdale,et al. Loss of skeletal muscle in cancer: biochemical mechanisms. , 2001, Frontiers in bioscience : a journal and virtual library.
[4] J. Fischer,et al. Muscle Cachexia: Current Concepts of Intracellular Mechanisms and Molecular Regulation , 2001, Annals of surgery.
[5] R. Bellantone,et al. Serum tumour necrosis factor‐α levels in cancer patients are discontinuous and correlate with weight loss , 2000, European journal of clinical investigation.
[6] P. Costelli,et al. Cancer cachexia: from experimental models to patient management. , 2000, Current opinion in clinical nutrition and metabolic care.
[7] C. Martínez-A,et al. Implication of calpain in caspase activation during B cell clonal deletion , 1999, The EMBO journal.
[8] Keiji Tanaka,et al. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats , 1999, Molecular Biology Reports.
[9] F. López‐Soriano,et al. Tumour growth and nitrogen metabolism in the host (Review). , 1999, International journal of oncology.
[10] N. Agell,et al. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. , 1998, Cancer letters.
[11] N. Agell,et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice , 1998, Molecular and Cellular Endocrinology.
[12] G. Cohen,et al. Proteasome activities decrease during dexamethasone-induced apoptosis of thymocytes. , 1998, The Biochemical journal.
[13] L. Tessitore,et al. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats. , 1996, Biochemical and biophysical research communications.
[14] S. Khera,et al. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines. , 1996, Leukemia & lymphoma.
[15] G. Strassmann,et al. Inhibition of experimental cancer cachexia by anti-cytokine and anti-cytokine-receptor therapy. , 1995, Cytokines and molecular therapy.
[16] L. Tessitore,et al. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway. , 1995, The Journal of clinical investigation.
[17] A. Goldberg,et al. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. , 1995, The American journal of physiology.
[18] N. Agell,et al. Muscle wasting associated with cancer cachexia is linked to an important activation of the atp‐dependent ubiquitin‐mediated proteolysis , 1995, International journal of cancer.
[19] J. Estrela,et al. Increased ATP-ubiquitin-dependent proteolysis in skeletal muscles of tumor-bearing rats. , 1994, Cancer research.
[20] L. Tessitore,et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. , 1993, The Journal of clinical investigation.
[21] R. Nordan,et al. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. , 1993, The Journal of clinical investigation.
[22] D. Breuillé,et al. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. , 1993, The American journal of physiology.
[23] L. Tessitore,et al. Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. , 1993, Archives of biochemistry and biophysics.
[24] P Ghezzi,et al. Suramin induces deoligomerization of human tumor necrosis factor alpha. , 1993, The Journal of biological chemistry.
[25] M. Koohmaraie. Ovine skeletal muscle multicatalytic proteinase complex (proteasome): purification, characterization, and comparison of its effects on myofibrils with mu-calpains. , 1992, Journal of animal science.
[26] M. Muscaritoli,et al. Abnormal substrate metabolism and nutritional strategies in cancer management. , 1991, JPEN. Journal of parenteral and enteral nutrition.
[27] Oliver H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[28] S. Warren. THE IMMEDIATE CAUSES OF DEATH IN CANCER , 1932 .
[29] T. Ogihara,et al. Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model , 1999, Gene Therapy.
[30] L. Tessitore,et al. Anti-tumour necrosis factor-alpha treatment interferes with changes in lipid metabolism in a tumour cachexia model. , 1994, Clinical science.
[31] G. Opdenakker,et al. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia. , 1991, European journal of cancer.
[32] W. Dewys. Weight loss and nutritional abnormalities in cancer patients: incidence, severity and significance , 1986 .